Frank Tong

Frank focuses on capital markets matters, particularly initial public offerings (IPOs), cross-border M&A and various other corporate transactions.

Frank is a native Cantonese and Mandarin speaker and is fluent in English.

Representative matters:

Capital markets

• Impact Therapeutics, a commercial-stage biopharmaceutical company focused on advancing synthetic lethality-based precision anticancer therapies globally, in its HK$844 million IPO and listing on the HKEX
• Butong Group, a company that specializes in the design and sale of nursery products, in its HK$781.84 million IPO
• Shanghai Bao Pharmaceuticals, a biopharmaceutical company focused on the industrialization and commercialization of recombinant protein and antibody-based therapeutics, in its HK$1 billion IPO and listing on the HKEX
• Nanjing Leads Biolabs, a clinical-stage biotechnology company focused on oncology and autoimmune and other severe diseases, in its HK$1.29 billion IPO and listing on the HKEX
• Hangzhou Jiuyuan Gene Engineering, a modern biopharmaceutical company engaged in the research and development, manufacture, and sale of gene engineering products, in its HK$563.9 million IPO and listing on the HKEX
• ImmuneOnco Biopharmaceuticals, a clinical-stage biotechnology company dedicated to the development of immuno-oncology therapies, in its HK$319 million IPO and listing on the HKEX and related post-listing compliance matters
• CICC and SPDB International as joint sponsors and underwriters’ counsel in the HK$583 million Hong Kong IPO of BrainAurora Medical Technology, a seasoned player in China’s cognitive impairment digital therapeutics market
• CICC and CMB International Securities as joint sponsors and underwriters’ counsel in the HK$1.005 billion IPO and listing of Zenergy, a lithium-ion battery manufacturer focusing on the research and development, production, and sales of electric vehicle, electrochemical energy storage and aviation battery products
• Shenwan Hongyuan Securities as sponsor’s counsel in Shanghai’s first change of listing venue, with Huaxin Cement changing its listing from the Shanghai Stock Exchange to the main board of the HKEX and listing its H shares by way of introduction*

Post-listing compliance

• Hangzhou Jiuyuan Gene Engineering
• ImmuneOnco Biopharmaceuticals
• Nanjing Leads Biolabs
• Shanghai Bao Pharmaceuticals
• Jinxin Fertility Group*
• WuXi Biologics (Cayman)*
• Chaoju Eye Care Holdings*

* Representation handled before joining Cooley